MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

Search

Guardant Health Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

50.68 -2.35

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

49.9

Max

52.07

Pagrindiniai rodikliai

By Trading Economics

Pajamos

16M

-95M

Pardavimai

1.7M

203M

Pelnas, tenkantis vienai akcijai

-0.49

Pelno marža

-46.768

Darbuotojai

1,999

EBITDA

-12M

-111M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+17.95% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

92M

6B

Ankstesnė atidarymo kaina

53.03

Ankstesnė uždarymo kaina

50.68

Naujienos nuotaikos

By Acuity

50%

50%

163 / 380 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-01 23:09; UTC

Uždarbis

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

2025-07-01 19:16; UTC

Įsigijimai, susijungimai, perėmimai

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

2025-07-01 23:47; UTC

Rinkos pokalbiai

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

2025-07-01 23:41; UTC

Rinkos pokalbiai

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

2025-07-01 22:23; UTC

Įsigijimai, susijungimai, perėmimai

James Hardie: Deal Represents Implied Value of $8.4 Billion

2025-07-01 22:23; UTC

Įsigijimai, susijungimai, perėmimai

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

2025-07-01 22:21; UTC

Įsigijimai, susijungimai, perėmimai

James Hardie Completes Acquisition of AZEK

2025-07-01 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-07-01 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-01 20:24; UTC

Uždarbis

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

2025-07-01 19:55; UTC

Rinkos pokalbiai

Oil Futures Resume Cautious Rally -- Market Talk

2025-07-01 19:27; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Lose More Ground -- Market Talk

2025-07-01 19:12; UTC

Rinkos pokalbiai

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

2025-07-01 19:01; UTC

Įsigijimai, susijungimai, perėmimai

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

2025-07-01 18:41; UTC

Įsigijimai, susijungimai, perėmimai

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

2025-07-01 18:33; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-07-01 18:33; UTC

Rinkos pokalbiai

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

2025-07-01 18:32; UTC

Rinkos pokalbiai

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

2025-07-01 18:22; UTC

Rinkos pokalbiai

Remittances to Mexico Down in May -- Market Talk

2025-07-01 17:45; UTC

Rinkos pokalbiai

Seasonal Demand Supports Further Oil Gains -- Market Talk

2025-07-01 17:01; UTC

Įsigijimai, susijungimai, perėmimai

Danone Completed Acquisition of Majority Stake in Kate Farms

2025-07-01 16:55; UTC

Uždarbis

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

2025-07-01 16:27; UTC

Rinkos pokalbiai

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

2025-07-01 16:25; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

2025-07-01 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-07-01 15:48; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

2025-07-01 15:46; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-07-01 15:46; UTC

Rinkos pokalbiai

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

2025-07-01 14:54; UTC

Rinkos pokalbiai

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

2025-07-01 14:49; UTC

Rinkos pokalbiai

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

17.95% į viršų

12 mėnesių prognozė

Vidutinis 61.38 USD  17.95%

Aukščiausias 70 USD

Žemiausias 56 USD

Remiantis 18 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

18 ratings

18

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

163 / 380 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.